ASTM Workshop on Hydrogel Characterization

ASTM International will host the Workshop on the Characterization of Hydrogel Medical Products on May 6, 2025, in Toronto, Canada, during the spring meeting of the ASTM Committee F04 on Medical and Surgical Materials and Devices. This event brings together leading experts to discuss best practices, emerging analytical techniques, and the urgent need for standardized testing methods for hydrogels used in medical devices.

Workshop Focus and Objectives

Hydrogels are increasingly vital in medical applications, from regenerative medicine to implantable devices, due to their unique properties as water-swollen, three-dimensional polymer networks. However, the lack of standardized characterization protocols presents challenges for manufacturers, regulators, and researchers. The workshop aims to:

• Review current analytical techniques for hydrogel characterization, including assessments of chemistry, morphology, mechanical properties, and in-use performance.
• Identify critical gaps in existing ASTM standards and discuss the need for new or improved test methods, particularly those relevant to both implantable and non-implantable hydrogel medical products.

• Foster collaboration among engineers, chemists, scientists, regulators, and industry stakeholders to advance the field and improve product safety and efficacy.

Who Should Attend

This workshop is designed for professionals involved in the development, testing, and regulation of hydrogel-based medical products, including:

• Medical device manufacturers
• Testing laboratories
• Regulatory agencies
• Pharmaceutical companies utilizing hydrogel technologies

Interactive Discussion and Next Steps

Attendees are encouraged to participate in an open discussion at the conclusion of the workshop to help shape the future of hydrogel test standardization. This collaborative session will be instrumental in determining priorities for new ASTM standards and identifying opportunities for further research and interlaboratory studies

Workshop Co-Chairs

• Stephen Spiegelberg, Cambridge Polymer Group
• Jon Moseley (Retired)

Featured Speakers and Presentations

Join the Conversation

Be part of the effort to shape the future of hydrogel medical product standards. Your expertise and input are vital to ensuring the safe and effective use of these soft materials in healthcare. For full event details and registration, visit the ASTM Workshop on the Characterization of Hydrogel Medical Products information page.

Microplastics in Infusion Bags

Microplastics have become a pressing topic in environmental and health discussions, with increasing attention from the media and scientific community. These tiny plastic particles, typically defined as ranging in size from 1 micrometer to 5 millimeters, can be composed of various types of polymers and are now being detected in an array of consumer products. A recent study by Huang et al. (2025)[1] examined the presence of microplastics in intravenous (IV) infusion bags, a common component of medical treatment.

What Are IV Infusion Bags?

IV infusion bags are flexible containers designed to deliver aqueous solutions, such as drugs, electrolytes, or saline, directly into a patient’s bloodstream. Given their direct interaction with the body, the potential presence of microplastics in these containers may be of concern.

Key Findings from Huang et al.’s Study

Huang’s study focuses of two brands of saline IV bags made from polypropylene. The contents of these bags were filtered, and the researchers employed Raman spectroscopy, scanning electron microscopy (SEM), and optical microscopy to identify and quantify the particles in the filtrate. The Raman spectroscopy confirmed that the particles were polypropylene. Particle counts revealed concentrations between 7020-7900 particles per liter of saline, with the majority (68%) measuring between 1-10 micrometers, and an overall size range of 1-62 micrometers.

The study did not speculate on how these microplastics entered the IV bags.

Health Implications

The authors note that microplastics have previously been discovered in human blood and adjacent organs, including the lungs, liver, kidneys, and spleen. Scientists at Cambridge Polymer Group are actively engaged in identifying and quantifying microplastics in products and tissues and in a recent study, we have detected microplastics in multiple lung tissue samples. The health implications of these microplastics remain uncertain at this time.

Regulatory Standards for Particulates

According to USP Particulate Matter in Injections, the limits for particles exceeding 10 micrometers should not surpass 12,000/L and 2,000/L for particles greater than 25 micrometers in containers holding more than 100 ml of solution. For containers with less than 100 ml, the limits are set at 3,000 particles (>10 micrometers) and 300 particles (>25 micrometers) per container. While the concentrations of microplastics found in Huang’s study fall within these regulatory limits for larger particles (>10 micrometers), the sheer number of smaller particles raises questions about whether current standards adequately address this emerging issue.

What’s Next?

The detection of microplastics in IV infusion bags highlights a critical gap in our understanding of their potential health impacts. Further research is needed to explore:

1. How microplastics enter medical products during manufacturing or storage.
2. The long-term effects of introducing microplastics into the human body through medical treatments.
3. Whether existing regulatory standards should be updated to account for smaller particles.

As scientists continue to investigate this issue, healthcare providers and manufacturers must remain vigilant about minimizing contamination risks. In parallel, regulatory bodies may need to revisit particulate limits to ensure patient safety in light of emerging evidence on microplastics.

By shedding light on studies like Huang et al.’s, we can better understand and address this growing concern—ensuring that medical products meet the highest standards of safety and efficacy.

[1] Huang, T., et al. (2025). “MPs Entering Human Circulation through Infusions: A Significant Pathway and Health Concern.” Environment & Health. https://doi.org/10.1021/envhealth.4c00210

Ensuring Trustworthy Third-Party Lab Data for Regulatory Success

Companies regularly rely on third-party laboratory testing data to support regulatory medical device and pharmaceutical submissions, particularly when lacking in-house expertise or facilities. The credibility of these third party laboratories is crucial to regulatory success, but recent actions by the FDA highlight the risks associated with unvetted or noncompliant third party data.

Escalating FDA Scrutiny on Data Integrity

The FDA recently published warning letters to laboratories in China and India with concerns about fraudulent or unreliable testing data from these laboratories. One warning letter to a Chinese laboratory[1] concerned data from cytotoxicity and sensitization studies conducted on different dates with nearly identical results, raising suspicion that the data was not genuine. A series of letters released to an Indian laboratory in 2024 and 2025 notified pharmaceutical companies that any in vitro studies conducted by this laboratory for new drug applications and abbreviated new drug applications must be repeated at different study sites that do not have data integrity concerns.[2]

These warning letters reinforce a memo released from the FDA in February, 2024, warning medical device manufacturers to carefully examine data from third party laboratories to ensure the data is reliable.[3]

“The FDA has noted an increase in unreliable testing data generated by third-party testing facilities on behalf of device manufacturers and sponsors. This has resulted in the FDA being unable to reach a substantial equivalence determination or otherwise authorize marketing for medical devices whose submissions rely on such data.” — FDA Notification, March 2025[4]

Consequences for Manufacturers and Patients

This surge in data integrity issues has led the FDA to reject entire submissions, preventing the agency from reaching substantial equivalence determinations or authorizing marketing for affected medical devices. When the FDA cannot rely on submitted data, not only are sponsors forced to repeat costly studies, but patient access to new devices is also delayed, and supply chains may be disrupted.

Cambridge Polymer Group’s Commitment to Data Integrity

At Cambridge Polymer Group, we recognize the regulatory and reputational risks associated with unreliable data. Our protocols follow published standards, with calibrated, verified equipment, rigorous data checks, and comprehensive review processes. All raw and processed data, as well as equipment information, are available for client and regulatory inspection, ensuring transparency and readiness for regulatory review.

Conclusion

The FDA’s ongoing focus on data integrity makes it clear: the cost of unreliable third-party testing is high, with potential for regulatory setbacks, financial loss, and reputational harm. Selecting a transparent, compliant, and reliable laboratory partner is essential for successful regulatory submissions and for maintaining patient and market trust.

[1] https://www.raps.org/news-and-articles/news-articles/2025/3/fda-admonishes-chinese-device-testing-lab-for-fals

[2] https://www.fda.gov/drugs/drug-safety-and-availability/fda-pharmaceutical-companies-certain-studies-conducted-raptim-research-pvt-ltd-are-unacceptable

[3] https://www.fda.gov/medical-devices/industry-medical-devices/fraudulent-and-unreliable-laboratory-testing-data-premarket-submissions-fda-reminds-medical-device

[4] https://www.fda.gov/medical-devices/industry-medical-devices/notifications-data-integrity-medical-devices

Thoughtful Design in Surgical Lighting: Balancing Usability, Durability, and Sustainability

Traditional headlamps (worn above) are cumbersome and don’t accommodate face shields.

A groundbreaking surgical task light has been introduced by MezLight in collaboration with Syensqo[1], demonstrating a thoughtful approach to product design by considering key factors such as:

• Customer needs
• Sustainability concerns
• Environmental durability
• Material suitability

Addressing Customer Needs: Enhanced Usability and Safety

Traditional surgical task lights are typically worn as headlamps by surgeons (see image above), which can become uncomfortable and cumbersome during extended procedures. The new MezLight task features an adjustable arm allowing for precise positioning and eliminating the burden of a headlamp. This design also accommodates the use of face shields, thereby prioritizing both usability and safety for surgeons.

Sustainability: Built for Repeated Use

In terms of sustainability, the task light has been engineered to withstand repeated cleaning and sterilization through steam sterilization using an autoclave, successfully enduring over 100 autoclave cycles. This capability ensures a long lifetime of repeated cleaning cycles for the product. As a result, the light has been designed to be robust enough for mechanical positioning and adjustment during surgical procedures over many repeated uses.

Material Selection: Meeting Rigorous Medical Standards

To meet the stringent requirements for mechanical performance and sterilization, the design team chose Radel®, a polyphenylsulfone (PPSU) supplied by Syensqo. This material was selected based on its exceptional properties:

• High heat deflection temperature of 207°C, ensuring stability under autoclave conditions and preventing deformation from the LED heat source.
• Good hydrolytic stability, enabling it to withstand repeated exposure to high-temperature steam without degradation
• Impact strength comparable to other durable plastics such as polycarbonate, ensuring mechanical integrity during use.

Radel® has also been historically used in surgical instrument handles and trays, proving its ability to endure multiple sterilization cycles.

A Model of Comprehensive Design

This surgical task light exemplifies the comprehensive considerations involved in material selection for medical products, while ensuring the fulfillment of customer needs. By addressing the unique challenges faced in surgical environments, this product not only meets the practical demands of healthcare professionals but also aligns with sustainability goals in medical device manufacturing.

[1] https://www.syensqo.com/en/press-release/syensqo-partners-mezlight-launch-worlds-first-sterile-reusable-surgical-task-light

Celebrating Rubber Band Day

Every year on March 17th, we commemorate the invention of the rubber band, patented by Stephen Perry in 1845. This innovation followed Charles Goodyear’s groundbreaking discovery in 1838 that adding sulfur to polyisoprene creates crosslinks, significantly enhancing its elastic properties. This breakthrough led to the development of rubber tires.

Composition of Rubber Bands

Rubber bands are traditionally made from polyisoprene, a polymeric elastomer derived from either the latex sap of rubber trees or petroleum products. They can also be made from ethylene propylene diene (EPDM) rubber and silicone. Polyisoprene rubber bands are prone to degradation, especially when exposed to sunlight, which causes them to become brittle over time. In contrast, silicone and EPDM rubber bands are more resistant to degradation.

Elastic Properties

Rubber bands are almost purely elastic, meaning they return to their original dimensions after being stretched and released without any permanent deformation. This elasticity is due to the crosslinks in the rubber that connect adjacent long polymer chains, forming a three-dimensional network. This process can be repeated multiple times without causing permanent deformation.

Thermal Dynamic Principles

In the mid-1800s, Lord Kelvin developed the theory of thermodynamics using rubber samples as examples of entropy principles. James Joule confirmed Kelvin’s theory with experiments showing that rubber samples increase in temperature when stretched. Two key principles underlie the thermodynamics of rubber bands:

1. Internal Energy Independence. The internal energy UU of a rubber band is independent of its length L0L0, expressed as U=cL0TU=cL0T, where TT is the temperature and cc is a constant
2. Linear Tension Increases. The tension σσ of a rubber band increases linearly with its length, given by σ=bTΔLσ=bTΔL, where bb is another constant and ΔLΔL is the change in length.

Kelvin described the thermodynamics of stretching a rubber band using the Helmholtz free energy (AA) expression: A=U−TSA=U−TS, where SS is the entropy of the system. AA represents the total energy available to do work. The internal energy UU includes potential and kinetic energy, expressed as U=Q−WU=Q−W, where QQ is heat added to the system and WW is work done by the system. Heat transfer can be written as dQ=TdSdQ=TdS, and work done on the rubber band as dW=σdLdW=σdL. Rearranging these expressions yields dF=σdL−SdTdF=σdL−SdT, where dFdF is the change in free energy, dLdL is the change in length, and dTdT is the change in temperature.

The temperature change in a rubber band is given by dT=dL(σ/S)−dF(1/S)dT=dL(σ/S)−dF(1/S). When a rubber band is stretched (dLdL positive), its temperature rises. Conversely, when it relaxes (dLdL negative), its temperature falls. At points where the rubber band is held at a fixed distance, heat either dissipates into the environment or the environment warms the cooled rubber band.

Molecular Alignment and Entropy

On a polymeric level, stretching a rubber band aligns and orders its molecules, decreasing entropy. When the rubber band relaxes, the polymer chains also relax, increasing entropy again.

Experimenting with Thermodynamics

You can easily demonstrate these principles by lightly placing a rubber band against your lips, which are sensitive to temperature, and moderately stretching it. You should feel a temperature rise. When the rubber band is relaxed, a cooling sensation should be noticeable. This simple experiment illustrates the effects of microscopic molecular motion.

Remember to wear safety glasses when conducting this test.

FDA Layoffs: Impact on Medical Device Review and Patient Safety

Over the February 15-16, 2025 weekend, the new U.S. administration laid off a substantial number of FDA reviewers from the Center for Device and Radiological Health (CDRH), the branch that reviews the safety and efficacy of new medical devices, including hip and knee implants, cardiovascular and respiratory devices, ophthalmological treatments, wound care, and thousands of other types of medical devices.

MDUFA Commitments and Funding Concerns

The Medical Device User Fee Amendments (MDUFA) program, funded by fees from medical device companies, was established to ensure timely and thorough reviews of new medical devices. Many of the laid-off employees were hired specifically to fulfill MDUFA commitments. This raises questions about:

• Resource allocation: How will the FDA maintain its review capacity with reduced staff?
• Financial implications: Given that user fees largely cover reviewer costs, the rationale behind these layoffs in terms of government spending remains unclear.

Potential Consequences of FDA Layoffs

Review Process Challenges

The reduction in the reviewer workforce is likely to have several immediate effects:

• Delayed reviews: Fewer reviewers may lead to longer wait times for device approvals.
• Compromised quality: The scientific rigor of reviews may be affected due to the increased workload on remaining staff.

Expertise Gaps

The layoffs have created critical gaps in specialized knowledge:

• AI expertise shortage: The layoffs also included reviewers with specialization in artificial intelligence. Given the trend towards incorporating AI into medical data interpretation and hardware responses, reviewers with this expertise are particularly needed at this time.
• Respiratory device oversight: The dismissal of half the subject matter experts in respiratory devices is alarming, especially given recent issues in this area.

Industry and Patient Impact

The FDA’s ability to advance regulatory science and facilitate medical device innovation may be compromised, potentially affecting the United States’ leadership position in the field.

The loss of experienced reviewers is likely to have far-reaching consequences:

• Medical device companies: May face longer approval timelines and increased uncertainty.
• Healthcare providers: Could experience delays in accessing new medical technologies.
• Patients: May face potential safety risks and delayed access to innovative treatments.

As the situation continues to evolve, medical device companies, healthcare providers, and patients should stay informed about potential impacts on device approvals and safety monitoring. We will continue to monitor the situation and advise our clients as we can.

Quantifying Rapid Rheological Changes

Blood vessel with hemostatic agent

In the world of material science and product design, understanding and measuring rheological transitions is crucial across many industries. These changes in the rheological properties, which can be triggered by stimuli such as motion, light, heat, electrical and magnetic fields, or chemical interactions, play a significant role in the successful use of these materials ranging from hemostatic agents through to consumer products and from paints and coatings to 3D printing materials. While standard methods exist for common applications, less conventional scenarios often lack specialized tools for accurate measurement.

The Challenge of Rapid Rheology Transitions

Conventional methods for measuring rapid rheological changes often face limitations:

1. Large sample volume requirements
2. Inability to capture transitions faster than one second
3. Lack of quantitative accuracy for rapid changes

For instance, the stir bar stop method, while useful for qualitative ranking, falls short in providing precise measurements for transitions occurring in less than a second.

Stir bar stop method typically used as a qualitative metric to measure near rapid rheological transitions. Example shown for crosslinking. Time accuracy is only as good as the human pressing the start/stop button on a stopwatch.

A Novel Approach: Custom Vane and Baffled Cup Geometry

To address these challenges in a specific use case for polymer rheology testing, the gelation of a hemostatic agent, an innovative method was developed using a custom-designed vane and baffled cup geometry. This approach offers several advantages:

• Reduced sample volume: Only 6 mL required, compared to ~20 mL for standard vane accessories
• Rapid mixing capability: High-speed rotation ensures near-instantaneous mixing
• Precise measurement: Captures transitions within seconds of stimulus application

Experimental Setup and Calibration

CAD sketch of custom vane (left) and custom baffled cup (middle). Machined vane and 3D printed baffled cup assembly (right).

The custom setup consists of:

1. A TA Instruments DHR-2 rheometer
2. A 3D-printed baffled cup
3. A CNC-machined aluminum vane fixture

Due to the smaller-than-recommended gap, the geometry required calibration using both concentric cylinder and parallel plate analogies to determine accurate stress and strain factors.

Measuring Rapid Absorption Kinetics

The method was applied to measure the absorption kinetics of a powder absorbent in a liquid “spill”:

1. The vane rotates rapidly in the liquid
2. Powder absorbent is added to the cup
3. Torque is monitored until a threshold is reached
4. The test switches to oscillatory mode to measure slurry modulus

Results and Implications

Powder absorbent added to liquid “spill.” Blue curve from the initial mix step: powder added at ~3.7 seconds, mixed rapidly for ~0.5 seconds until a predetermined torque threshold was surpassed indicating the slurry was sufficiently mixed. Red (G’) and green (G”) curves: modulus growth kinetics shows crossover within ~1.8 seconds after addition of powder and full absorbency within 17.9 seconds from addition of powder.

The custom method yielded impressive results:

• Crossover time: 1.79 seconds after powder addition
• Full absorbency: Achieved within 17.85 seconds

These precise measurements provide valuable insights into the rapid rheological changes occurring in the absorbent material system.

Conclusion

This novel approach to quantifying rapid rheological changes offers a powerful tool for material scientists and product designers. By overcoming the limitations of conventional methods, it enables more accurate and detailed analysis of fast-acting materials, potentially leading to improved designs in various applications, from spill cleanup to medical treatments. The ability to capture such rapid transitions with minimal sample volumes opens new possibilities for research and development in fields where material behavior in the first few seconds is critical. As we continue to push the boundaries of material science, tools like this will play an increasingly important role in understanding and optimizing rapid rheological phenomena.

FDA’s Regulatory Freeze: Implications for Medical Device Standards and Patient Safety

Medical device development relies heavily on standards to ensure patient safety, efficacy, and regulatory compliance. Organizations such as ASTM, AAMI/ISO, and USP establish critical test methods to ensure adequate cleaning and sterility, mechanical performance, biocompatibility, and material integrity. These standards streamline innovation while safeguarding patients, reducing redundant testing, and maintaining U.S. competitiveness in global markets.

The FDA’s Critical Role in Standards Development

For decades, FDA scientists and regulators have been active participants in shaping these medical device standards and often hold leadership roles on individual standards or committees. Their direct experience with reviewing ~20,000 medical device submissions per year renders their input invaluable on both the types of standards needed and the specific content needed within those standards. Because biomedical technology is advancing rapidly, particularly in design innovation and material selection, it is critical to patient safety that standards keep pace. Up-to-date standards not only protect patients but also benefit U.S. companies by streamlining the regulatory process. With well-defined, current standards, US manufacturers can focus on conducting only the studies necessary for patient safety, and avoid unnecessary, costly and time-consuming testing that would put them at a disadvantage in the global market.

Executive Order Freezes Communication and Participation in Standards Development

A chair of an AAMI working group announced last week that the FDA will be pulling away from communication and participation in standards development within AAMI and ISO as a result of a January 20, 2025 executive order from the White House. Other FDA scientists confirmed the freeze applies to all regulatory activities, including their ASTM participation. The freeze is not a permanent cessation of standard development activities, but no timeline has been given.

Risks of Reduced FDA Participation

Without FDA’s frontline regulatory experience, standards may lag behind medical device advancements, in areas such as AI-driven devices, nanotechnology, and biocompatible materials. Outdated standards could fail to address emerging risks, including cybersecurity vulnerabilities in connected devices or novel biomaterial interactions. U.S. manufacturers may face redundant testing to meet divergent global standards, increasing costs and time-to-market compared to international competitors.

If the freeze becomes permanent, the lack of FDA participation in standards development is likely to increase the regulatory and development burden, and therefore increase costs on American medical device manufacturers, causing delays to get products on the market and potentially put patients at risk. We sincerely hope that the new administration permits continued involvement of FDA personnel in the standards process.

NAMSA Acquisition of U.S. Medical Device Testing Operations of WuXi AppTec

NAMSA, a medical device contract research organization, announced last week the acquisition of the US medical device testing operations of WuXi AppTec, a biopharmaceutical and medical device testing laboratory headquartered in China. This acquisition is part of a recent trend of acquisitions of medical device testing laboratories by larger multinational testing conglomerates over the past few years. This trend, predicted to continue, results in larger, consolidated operations with higher volumes and the ability to offer routine standardized testing on complex projects. However, it comes with a cost.

Challenges in Biological Safety Evaluation

Evaluation of the biological safety of medical devices with compliance to new standards and revisions of existing standards has become increasingly challenging.  Given the shift in regulatory expectations, along with an increase in the use of unique materials and manufacturing processes, each premarket submission often requires a custom-designed strategy for assessing biological safety that takes in to account the details of the device’s indication and composition.  This approach dictates constant communication between engineers and regulatory affairs specialists at the medical device manufacturer, the research lab conducting the biological endpoint and chemical characterization testing, and the toxicologists and biologicals safety specialists conducting the biological evaluation and making a final determination on safety.

CPG’s Collaborative Approach to BSE

Material scientist and biocompatibility specialists at Cambridge Polymer Group work directly with the client through the submission process to ensure a successful outcome with regards to evaluation of the biological safety of the device.  Although communication often begins with a conversation between a single engineer at a medical device company and a scientist at CPG, CPG in-house experts often become part of the cross-functional team that is necessary to effectively address FDA feedback. As needed, CPG can also rapidly bring in additional external expertise to further support the submission process.

The customer-driven, interactive approach offered by CPG has resulted in a high success rate with premarket submissions. Ultimately, the support offered by in-house experts at CPG, along with external partners to CPG, can reduce the timeline and overall cost for bringing a medical device to market.  Turnkey contracts for biological safety evaluation may increase the risk that the premarket submission does not meet current regulatory expectations.

INEOS ABS Closure: Impact on Medical Device Manufacturers

The recent announcement of INEOS’s decision to permanently close its ABS (acrylonitrile butadiene styrene) production facility in Addyston, Ohio, has sent ripples through the medical device manufacturing industry. This closure, set to begin in the second quarter of 2025, will significantly impact manufacturers who rely on ABS plastics for various medical applications. The situation calls for a comprehensive strategy to address supply chain challenges and regulatory requirements.

Understanding ABS and Its Applications in Medical Devices

ABS is a versatile thermoplastic polymer widely used in the medical device industry due to its durability, chemical resistance, ease of processing, and biocompatibility. Applications include:

• Diagnostic equipment housings, including imaging machines and laboratory instruments
• Drug delivery devices, such as nebulizers, auto-injectors, and portable drug delivery systems
• Intravenous Access Devices, including components of IV connectors and luers
• Respiratory care devices, such as ventilator valves, medical masks, and tracheal tubes
• Non-absorbable sutures and tendon prostheses

ABS can be sterilized using methods like ethylene oxide gas, gamma radiation, or steam. The material can be easily colored and shaped to meet specific design requirements.

Challenges for Medical Device Manufacturers: Supply Chain Disruptions

The closure of the Addyston facility may lead to potential shortages and longer lead times for ABS materials. Manufacturers will need to diversify their supplier base and potentially look for alternative sources.

Cost Implications: A change in the ABS supplier could result in ship holds during qualification of a new supplier, resulting in a loss of profit from medical device sales. Further, the supplier change could impact material costs, potentially affecting the cost of medical devices.

Quality and Regulatory Concerns: ABS from new suppliers will need to be qualified to ensure that safety and effectiveness have not been impacted. 

Innovation Pressure: This situation may accelerate the exploration of alternative materials to reduce dependency on traditional ABS.

Specific Healthcare Manufacturing Aspects

1. Drug Delivery Systems. Impact: Potential redesign of portable drug delivery devices and auto-injectors
2. Diagnostic Equipment. Impact: Possible delays in production of imaging machine housings and laboratory instruments
3. Respiratory Care. Impact: Potential shortages of components for ventilators and other respiratory devices
4. Surgical Instruments. Impact: Possible delays in production of certain non-absorbable sutures and prostheses

In each of these areas, the challenge will be maintaining biocompatibility and device specifications with new materials.

Regulatory Challenges

Qualifying new ABS suppliers involves navigating complex regulatory pathways, which vary based on the device’s risk classification. For 510K cleared devices, a supplier change can be documented with a letter to file that confirms verification with the new material or, if the new material impacts safety or effectiveness, in a new 510(k) submission.  For PMA cleared devices, a supplier change can be documented in the annual report or, if the new material impacts safety or device effectiveness, in a PMA supplement.  

How CPG Can Help

CPG can assist medical device manufacturers in developing a tailored regulatory strategy for qualifying new ABS suppliers. This strategy will consider:

1. Supplier Qualification Process: Developing criteria for selecting and evaluating new ABS suppliers based on FDA expectations, as well as REACH, RoHS, Prop-65, and MDR compliance.
2. Testing Protocol Development: Designing and implementing necessary tests to qualify ABS to ensure safety and effectiveness of the device have not been impacted. 
3. Regulatory Documentation Preparation: Assistance in preparing documentation that support the continued safety and effectiveness of the device, including biological risks assessments, memos, and letters to file. If necessary due to a change in safety or effectiveness, CPG can also assist in the preparation of new 510(k) submissions and PMA supplements.

By leveraging CPG’s services, medical device manufacturers can navigate this supply chain challenge efficiently, minimizing disruptions to their production and market access while maintaining regulatory compliance. Collaboration between manufacturers, regulators, and material scientists will be crucial to maintain the quality and availability of essential medical products.